Versatile Amplification Method for Single-Molecule Detection in Liquid Biopsy

Project Information

VerSiLiB

Grant agreement ID: 101046217

DOI

10.3030/101046217

Project closed

EC signature date 21 March 2022

Start date 1 April 2022

End date 31 March 2026

Funded under

• The European Innovation Council (EIC)

Total cost

€ 2 994 244,99

EU contribution

€ 2 994 244,99

Coordinated by

TEKNOLOGIAN TUTKIMUSKESKUS VTT OY
Finland

Periodic Reporting for period 2 - VerSiLiB (Versatile Amplification Method for Single-Molecule Detection in Liquid Biopsy)

Reporting period: 2023-04-01 to 2024-09-30

Summary of the context and overall objectives of the project

Project aims to develop a proof-of-concept of a novel in-vitro diagnostic system that combines the analysis of DNA and protein biomarkers into one proteogenomic test. Project is the first step to enable fast and easy-to-use proteogenomic tests that will be widely applicable in the diagnosis of several significant diseases including viral outbreaks, cancers, and neuro-degenerative, immune and cardiovascular diseases. In the end of the project, the developed technology will be validated for real-life cancer management in a clinical setting.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Work during the first 2.5 years of the project has focused on:
• Defining system specifications
• Development of the sensor test chemistry for protein and DNA assay
• Design and implementation of the second version of the microfluidic chip
• Design and development of the integrated hardware prototype
• Conducting simulations and theoretical analyses
• Development of reference tests and standards of truths
• Collection of clinical samples

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Work to develop diagnostic system based on novel Affinity Mediated Transport amplification method has continued in close collaboration of the highly multi-disciplinary consortium combining expertise in molecular biology, chemistry, physical sciences, engineering, and medicine. During the 2.5 years of the project, the consortium has focused on finding solutions to the joint challenges with test chemistry and hardware design. Once the system is successfully developed and its foreseen advantages are demonstrated, it has potential to impact widely to the proteogenomic analyses in medical but also in other application fields utilizing molecular analysis.